Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex.
The purpose of the present study was to determine the effects of muscarinic cholinergic receptor antagonists and agonists on prepulse inhibition (PPI) of the acoustic startle reflex in rats. The muscarinic receptor antagonist scopolamine (0.03-1.0 mg/kg) produced a significant dose-dependent decrease in PPI without affecting startle amplitude. In contrast, N-methyl scopolamine, the quaternary analog of scopolamine, had no effect on PPI, indicating that scopolamine disrupted PPI through a central cholinergic mechanism. Two other muscarinic receptor antagonists, trihexyphenidyl (0.3-10 mg/kg) and benztropine (0.03-10 mg/kg), produced significant decreases in PPI similar to scopolamine. On the other hand, the muscarinic receptor antagonists dicyclomine (0.03-10 mg/kg) and biperiden (0.03-10 mg/kg) had no effect on PPI but significantly decreased startle amplitude. Mecamylamine (0.1-10 mg/kg), a nicotinic receptor antagonist, also had no effect on PPI. Administered alone, the muscarinic receptor agonists pilocarpine (0. 03-10 mg/kg), oxotremorine (0.01-0.3 mg/kg), RS-86 (0.1-3.0 mg/kg), and arecoline (0.3-10 mg/kg), as well as the cholinesterase inhibitors physostigmine (0.01-0.3 mg/kg) and tacrine (0.03-10 mg/kg), had no effect on PPI, but each produced significant decreases in startle amplitude at the highest doses tested. In addition, the disruption of PPI by scopolamine was reversed in a dose-dependent manner by the muscarinic receptor agonist oxotremorine. The present findings demonstrate that the muscarinic cholinergic system plays an important role in the normal mechanisms of PPI.
Jones
C K
CK
Program of Medical Neurobiology, Indiana University School of Medicine; and The Lilly Research Laboratories, Eli Lilly and Company, Indianapolis 46285, USA. Jones_Carrie_K@Lilly.com
Shannon
H E
HE
D000161:Acoustic Stimulation; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology; D018721:Muscarinic Agonists / Q000494:pharmacology; D018727:Muscarinic Antagonists / Q000494:pharmacology; D018733:Nicotinic Antagonists / Q000494:pharmacology; D010095:Oxotremorine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology*; D012018:Reflex; D013216:Reflex, Startle / Q000502:physiology*; D012601:Scopolamine / Q000494:pharmacology; D013329:Structure-Activity Relationship
D002800:Cholinesterase Inhibitors; D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D018733:Nicotinic Antagonists; D011976:Receptors, Muscarinic; D010095:Oxotremorine; D008464:Mecamylamine; D012601:Scopolamine